Priscilla K. Brastianos
A5015428519- Brain Metastases and Treatment
- Glioma Diagnosis and Treatment
- Lung Cancer Research Studies
- Meningioma and schwannoma management
- Lung Cancer Treatments and Mutations
- Pituitary Gland Disorders and Treatments
- Cancer Immunotherapy and Biomarkers
- Neurofibromatosis and Schwannoma Cases
- Radiopharmaceutical Chemistry and Applications
- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
- Chemical Reactions and Isotopes
- Head and Neck Surgical Oncology
- Ferroptosis and cancer prognosis
- Bone Tumor Diagnosis and Treatments
- Melanoma and MAPK Pathways
- Click Chemistry and Applications
- Radiomics and Machine Learning in Medical Imaging
- Nanoplatforms for cancer theranostics
- Chromatin Remodeling and Cancer
- Synthesis and Biological Evaluation
- Adrenal and Paraganglionic Tumors
- CNS Lymphoma Diagnosis and Treatment
- Immune cells in cancer
- Cancer therapeutics and mechanisms
Massachusetts General Hospital
2016-2025
Harvard University
2016-2025
Broad Institute
2014-2025
Dana-Farber Cancer Institute
2013-2024
Center for Neuro-Oncology
2012-2024
MGH Institute of Health Professions
2019-2024
Brigham and Women's Hospital
2011-2023
Dana-Farber Brigham Cancer Center
2009-2023
Ludwig-Maximilians-Universität München
2023
Woman's Hospital
2023
Abstract Brain metastases are associated with a dismal prognosis. Whether brain harbor distinct genetic alterations beyond those observed in primary tumors is unknown. We performed whole-exome sequencing of 86 matched metastases, tumors, and normal tissue. In all clonally related cancer samples, we branched evolution, where metastatic sites shared common ancestor yet continued to evolve independently. 53% cases, found potentially clinically informative the not detected primary-tumor sample....
Tumor subclasses differ according to the genotypes and phenotypes of malignant cells as well composition tumor microenvironment (TME). We dissected these influences in isocitrate dehydrogenase (IDH)-mutant gliomas by combining 14,226 single-cell RNA sequencing (RNA-seq) profiles from 16 patient samples with bulk RNA-seq 165 samples. Differences between IDH-mutant astrocytoma oligodendroglioma can be primarily explained distinct TME signature genetic events, whereas both types share similar...
Meningiomas are the most common primary intracranial tumor in adults. Identification of SMO and AKT1 mutations meningiomas has raised possibility targeted therapies for some patients. The frequency such clinical cohorts presence other actionable important to define.We used high-resolution array-comparative genomic hybridization prospectively characterize copy-number changes 150 then characterized these samples AKT1, KLF4, NF2, PIK3CA, SMO, TRAF7.Similar prior reports, we identified a subset...
We recently reported that BRAF V600E is the principal oncogenic driver of papillary craniopharyngioma, a highly morbid intracranial tumor commonly refractory to treatment. Here, we describe our treatment man age 39 years with multiply recurrent craniopharyngioma using dabrafenib (150mg, orally twice daily) and trametinib (2mg, daily). After 35 days treatment, volume was reduced by 85%. Mutations mediate resistance MAPK pathway inhibition were not detected in post-treatment sample whole exome...
Abstract Background Variability in standard-of-care classifications precludes accurate predictions of early tumor recurrence for individual patients with meningioma, limiting the appropriate selection who would benefit from adjuvant radiotherapy to delay recurrence. We aimed develop an individualized prediction model risk combining clinical and molecular factors meningioma. Methods DNA methylation profiles clinically annotated samples across multiple institutions were used a methylome 5-year...
Pediatric low-grade gliomas (PLGGs) are among the most common solid tumors in children but, apart from BRAF kinase mutations or duplications specific subclasses, few genetic driver events known. Diffuse PLGGs comprise a set of uncommon subtypes that exhibit invasive growth and therefore especially challenging clinically. We performed high-resolution copy-number analysis on 44 formalin-fixed, paraffin-embedded diffuse to identify recurrent alterations. exhibited fewer such alterations than...
A recent meeting was held on March 22, 2019, among the FDA, clinical scientists, pharmaceutical and biotech companies, trials cooperative groups, patient advocacy groups to discuss challenges potential solutions for increasing development of therapeutics central nervous system metastases. key issue identified at this need consistent tumor measurement reliable response assessment, including first step standardized image acquisition with an MRI protocol that could be implemented in multicenter...
Expanding the US Food and Drug Administration-approved indications for immune checkpoint inhibitors in patients with cancer has resulted therapeutic success immune-related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence of 1%-12% a high fatality rate relative to other irAEs. Lack standardized disease definitions accurate phenotyping leads syndrome misclassification impedes development evidence-based treatments translational research. The objective this study was develop...
Abstract Purpose: Patients with KRAS-mutant non–small cell lung cancer (NSCLC) brain metastases (BM) have a poor prognosis. Adagrasib (MRTX849), potent oral small-molecule KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state. has been optimized for favorable pharmacokinetic properties, including long half-life (∼24 hours), extensive tissue distribution, dose-dependent pharmacokinetics, central nervous system penetration; however, BM-specific...
Craniopharyngiomas, primary brain tumors of the pituitary-hypothalamic axis, can cause clinically significant sequelae. Treatment with use surgery, radiation, or both is often associated substantial morbidity related to vision loss, neuroendocrine dysfunction, and memory loss. Genotyping has shown that more than 90% papillary craniopharyngiomas carry